news

Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel α-Klotho Protein Therapy

October 25, 2025

Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia (XLH)

July 24, 2025

Anzor Pharmaceuticals Selected to Present at the Prestigious BioLabs-NYU Investor & Innovator Exchange

May 6, 2025

Anzor Pharmaceuticals to Present at Chronic Kidney Disease Conference

March 19, 2025

Anzor Pharmaceuticals Licenses Key Fibroblast Growth Factor Technology From New York University

February 20, 2025

© 2024 Anzor. All rights reserved.